Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18738729 | 0.83 | HSP90AB1 (0.37) | — | |
| SCHEMBL11640381 | 0.81 | ALOX5 (0.45) | MEN1HTTKMT2ALMNAALDH1A1 | |
| SCHEMBL18416742 | 0.80 | HTT (0.48) | MEN1HTTKMT2ALMNAALDH1A1 | |
| SCHEMBL13723487 | 0.79 | TSHR (0.38) | MEN1HTTKMT2ALMNAALDH1A1 | |
| SCHEMBL18703862 | 0.79 | MAPT (0.50) | MEN1HTTKMT2ALMNAALDH1A1 | |
| SCHEMBL13722908 | 0.79 | CYP1A2 (0.44) | MEN1HTTKMT2ALMNAALDH1A1 | |
| SCHEMBL31347504 | 0.78 | ACHE (0.54) | MEN1HTTKMT2ALMNAALDH1A1 | |
| SCHEMBL11025268 | 0.78 | ACHE (0.54) | MEN1HTTKMT2ALMNAALDH1A1 | |
| SCHEMBL15719607 | 0.78 | LMNA (0.44) | MEN1HTTKMT2ALMNAALDH1A1 | |
| SCHEMBL31347505 | 0.77 | ALDH1A1 (0.46) | MEN1HTTKMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408222-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2024-12-12 | — | — | US | disclosed |
| EP-4412655-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | Vincerx Pharma GmbH (DE) | 2024-08-14 | — | — | EP | disclosed |
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| WO-2023057812-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-08 | — | — | US | disclosed |
| US-20220267353-A1 | PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-25 | — | — | US | disclosed |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-02-22 | — | — | US | disclosed |
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-08 | — | — | US | disclosed |
| EP-3601253-B1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AG (DE) | 2021-09-15 | — | — | EP | disclosed |
| CN-108290903-B | Novel macrocyclic sulfondiimine compounds | 拜耳医药股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-9963464-B2 | Macrocyclic compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-08 | — | — | US | disclosed |
| WO-2017060167-A1 | NOVEL MODIFIED MACROCYCLIC COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017060322-A2 | PTEFB-INHIBITOR-ADC | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017060322-A2 | PTEFB-INHIBITOR-ADC | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | WO | disclosed |
| CN-106459084-A | Novel macrocyclic compounds | 拜耳医药股份有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-3129387-A1 | NOVEL MACROCYCLIC COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2017-02-15 | — | — | EP | disclosed |
| US-20170029439-A1 | NOVEL MACROCYCLIC COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-02 | — | — | US | disclosed |
| US-20170029439-A1 | NOVEL MACROCYCLIC COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-02 | — | — | US | disclosed |
| WO-2015155197-A1 | NOVEL MACROCYCLIC COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015155197-A1 | NOVEL MACROCYCLIC COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029439-A1 | NOVEL MACROCYCLIC COMPOUNDS | PCNA, CCNI, PKD1 | MEN1 256/4885HTT 1731/4885KMT2A 4178/4885 |
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | MEN1 647/4885HTT 3326/4885KMT2A 3422/4885 |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PKD1, RHEB | MEN1 803/4885HTT 3917/4885KMT2A 3620/4885 |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | MEN1 647/4885HTT 3326/4885KMT2A 3422/4885 |
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | MEN1 647/4885HTT 3326/4885KMT2A 3422/4885 |
| US-20240408222-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | PTK2, PCNA, CDK4 | MEN1 749/4885HTT 4516/4885KMT2A 2446/4885 |
| US-20220267353-A1 | PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PPIB, RHEB | MEN1 647/4885HTT 3326/4885KMT2A 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.